AIKENING Gx390 Recoil Starter Pull Start Assembly with Recoil Starter Rope Pull for Honda Recoil Starter(Pack of 2) Recoil Starter Rope X3 Bolts X9

Product Information

The TALENT study (TALENT) findings, which were presented at the 11th International AIDS Society (IAS) Conference on HIV Science, showed that a two-drug regimen was as effective and safe as multi-drug therapies In May 2018, Aikening® received a new drug certificate from the State Drug Administration in China. In October 2018, Aikening® was included as one of the major antiretroviral drugs available in the Chinese guidelines for diagnosis and treatment of HIV/AIDS (2018) issued by the Chinese Medical Association's Infectious Diseases Unit and the China Center for Disease Control and Prevention. In December 2020, Aikening® was enlisted as an exclusive patented product in the National List of Essential Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drugs (2020).

It is unknownwhether Albuvirtideis excreted in human breast milk. Mothers with HIV-infectionsshould not breast-feed infants so as to avoid HIV transmission. Mothers should not breastfeed infantsif they are receiving AIKENING TM. Step 2: Inject 1.2 mL of 5%sodium bicarbonate solution into each vial, shake or vortex the vial thoroughly to form solution.Wu H, Yao C, Zhang T, et al. Efficacy and safety of long acting HIV fusion inhibitor albuvirtide in treatment-experienced HIV-1 infected patients: Week 48 analysis from the randomized controlled phase 3 TALENT study. Poster presented at: IAS Conference on HIV Science; July 18-21, 2021. Accessed April 5, 2023 Participants have HIV RNA <50 copies/mL at screening and have had HIV RNA <50 copies/mL in the past 24 weeks prior to screening. Founded in 2013, Frontier Biotechnologies Inc. ("Frontier Biotech") is a commercial-stage biopharmaceutical company headquartered in China with global vision and world-class competitiveness. Frontier Biotech is committed to discovering, development, manufacturing, and commercialization of innovative medicines that improve patient health. The pharmacokinetic study has not yet been conducted in children under 16 years old and elderly above 65 years old.

Note: It will be difficult to control the volume of sodium bicarbonate solution injected into the vial as the vials are sealed under vacuum (negative air pressure) which will likely create a suction. Aikening® in combination with other antiretroviral treatment is effective for both major and drug-resistant viral strains. In a real world setting, Aikening® was widely accepted as one of the ARTs for patients with high unmet needs such as HIV hospitalization and critically-ill patients, liver and kidney dysfunctional patients and multiple drug-resistant patients due to the new mode of administration (once-weekly injection), lower pill burden, fast onset of action, high resistance barrier and well tolerated safety profile. Purpose: The purpose of this study is to evaluate the safety of combination therapy with albuvirtide plus 3BNC117 and determine whether this combination can control viral load levels after an analytical treatment interruption of ART. 9On September 29, 2021, an article entitled Tolerability and Adherence of Antiretroviral Regimens Containing Long-Acting Fusion Inhibitor Albuvirtide for HIV Post-Exposure Prophylaxis: A Cohort Study in China was published in the international medical journal -- Infectious Diseases and Therapy. This clinical study is the world’s largest and China’s first prospective cohort study on the HIV PEP population to evaluate the safety, tolerability and adherence of the combination regimens of ABT with other oral drugs for HIV PEP. This study is supported by reliable sources of clinical studies and data collection, providing a clinical reference for evidence-based use in the treatment of HIV PEP.

Purpose: The purpose of this study is to establish the optimal dosage of a regimen consisting of albuvirtide plus the investigational broadly neutralizing antibody (bNAb) 3BNC117. The study will also evaluate the safety and effectiveness of this regimen as maintenance therapy. 8 Zhang H, Jin R, Yao C, et al. Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients. AIDS Res Ther. 2016;13. Accessed April 4, 2023 The results of the randomized controlled, open-labelled, multicenter, non-inferiority study showed successful achievement of the primary endpoint, with a good proportion of patients on the ABT regimen with HIV RNA less than 50 copies/mL at 48 weeks. The drug demonstrated efficacy against major strains of HIV, including resistant strains. Rodríguez-González, V.; Obregón, S.; Patrón-Soberano, O.A.; Terashima, C.; Fujishima, A. An approach to the photocatalytic mechanism in the TiO 2-nanomaterials microorganism interface for the control of infectious processes. Appl. Catal. 2020, 270, 118853. [ Google Scholar] [ CrossRef]

Participants are adults with HIV on a stable ART regimen who initiated ART either within 6 months of primary HIV infection (cohort 1) or after 6 months of primary HIV infection (cohort 2).